Skip to content

Study of Cyclodxtrin Therapy for Niemann-Pick disease Type C

Study of Intrathecal or Intracerebroventricular administration of Cyclodextrin for Niemann-Pick disease Type C - ITaC study

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs071190008
Enrollment
3
Registered
2019-05-17
Start date
2019-07-03
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Niemann-Pick disase, type C Lysozome disease, cholesterol

Interventions

Treatment with intrathecal administration of cyclodextrin
Cyclodextrin, intrathecal administration

Sponsors

Matsuo Muneaki
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Genetically proven Niemann-Pick disease type C 2)From two year-old to fifteen year-old patient with apparent neurological symptom. 3)Possibility of regular intrathecal administration by lumbar puncture. 4)Possibility of repeated regular visits to Saga University Hospital. 5)Miglustat should be taken at least three months with a constant dosage before the baseline assessment. 6)The patient or the guardian understand poor life prognosis of this intractable disease and no established treatment for it. 7)The patient or the guardian understand that the safety and efficacy of HPBCD is not established,and unexpected adverse events which can lead to a life threatening sequelae could be occurred. 8)The patient or guardian understand risks for lumber puncture. 9)The patient or guardian understand that this treatment will be done in a limited period.

Exclusion criteria

Exclusion criteria: 1)The age at registration is less than two year-old or more than sixteen year-old. 2)No neurological symptoms. 3)Past history of hypersensitivity reaction to cyclodextrin or its additives. 4)Suspected central nervous system infection or systemic infection. 5)Difficulty of lumbar puncture due to spinal anomaly. 6)Skin infection of the lumbar puncture site. 7)Neutropenia (less than 1,000/mm3) 8)Thrombocytopenia (less than 50,000/mm3) 9)Circulation abnormality in cerebrospinal fluid. 10)Use of anti-coagulants or bleeding tendancy. 11)Acute hepatic disease with jaundice or right upper abdominai pain. 12)Anemia which is less than 2SD of the age and sex standards.

Design outcomes

Primary

MeasureTime frame
Change ratio of modified disability scale for NPC between before and after treatment

Secondary

MeasureTime frame
Change in EEG,hearing,MRI

Contacts

Public ContactMuneaki Matsuo

Saga University Hospital

matsuo@cc.saga-u.ac.jp+81-952-34-2314

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026